LYOCONTRACT GmbH, based in Ilsenburg, is a leading contract manufacturer for pharmaceutical products, specialized in producing liquid and freeze-dried parenteral pharmaceuticals in vials. The core business comprises processing customer-owned raw materials as well as procuring and providing active ingredients and performing aseptic production or terminal sterilization. The service portfolio includes quality controls for active, raw and excipient materials, in-process controls, release testing and stability studies as well as process and method transfers and validations. After manufacturing products are labeled, packaged and services such as serialization are provided; in the shortened financial year 2024 the company reported increased customer demand and higher production volumes.
Die Herstellung von biopharmazeutischen Grundstoffen (API, Active Pharmaceutical Ingredients) sowie die Herstellung, der Vertrieb und die Auftragsherstellung von Medikamenten (Outsourcing), Enzymen, Hormonen, Organextrakten, Antibiotika und Zytostatika sowie medizinischen Diagnostika, Export-Import von Medikamenten, medizinischer Diagnostika und medizinischen Einrichtungen und medizinischem Bedarf.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Stendal Local Court, HRB 17980 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Tino Galgon | Geschäftsführer(in) | Dessau-Roßlau |
Source: German Commercial Register (Handelsregister) Stendal Local Court, HRB 17980 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€11.2M2 | €4,522,201 | €21,208,923 | — |
| 2023 | Rohergebnis€21.5M2 | €4,748,582 | €17,965,258 | — |
| 2022 | €21,613,885 | €4,215,603 | €15,362,026 | — |
| 2021 | €15,949,315 | €2,158,897 | €10,980,118 | — |
| 2020 | — | €582,207 | €5,675,063 | — |
| 2019 | — | €823,068 | €5,139,148 | — |
| 2018 | — | €388,870 | €4,365,425 | — |
| 2017 | — | €0 | €3,447,992 | — |
| 2016 | — | — | €2,702,673 | — |
| 2015 | — | — | €2,389,922 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Stendal Local Court, HRB 17980 (as of 31 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,258,252 | 98.5% |
| Depreciation | €61,434 | 1.4% |
| Interest & Similar | €1,316 | 0.0% |
